Medical Health & Life Science Research News

New study: Nanoparticles market in biotechnology and pharmaceutical sectors 2017-2021

Medical Market Research

MRC recognizes the following companies as the key players in the global nanoparticles market in biotechnology and pharmaceutical sectors: F. Hoffmann-La Roche, GE Healthcare, Merck, and Novartis. Other Prominent Vendors in the market are: AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire, and UCB.

"MRC Announces the Publication of its Research Report – Global Nanoparticles Market in Biotechnology and Pharmaceutical Sectors 2017-2021

Commenting on the report, an analyst from MRC’s team said: “The latest trend gaining momentum in the market is Increasing demand for nanoparticles in stem cell therapy. Stem cells have the remarkable potential of developing into different cell types in the body during early life and growth.

Stem cells function as an internal repair system that divides to replenish other cells so long the animal or person is alive. Stem cells include embryonic stem cells and non-embryonic adult stem cells that are unspecialized cells.

Advancements in stem cell research expose the tremendous potential of stem cells that can change the face of diseases and how we perceive them.”

Request Sample Copy of the Report @ marketreportscenter.com/request-sample/564967

According to the report, one of the major drivers for this market is Rising R&D expenditure in pharmaceutical and biotechnology sectors. The pharmaceutical industry is witnessing a global surge in research funding to combat various rare diseases developing globally or to explore new therapies for existing conditions.

The pharmaceutical R&D spending is expected to increase by 4% between 2016 to 2022. Biotechnology companies are also making increased investments in R&D.

The US was the largest investor in biotechnology R&D in 2015 investing around $28 billion. France was the second largest investor in biotechnology R&D in 2015 investing over $3.6 billion, followed by Switzerland investing over $2.8 billion.

South Korea was the largest investor in biotechnology R&D in Asia, investing over $1.7 billion.


Further, the report states that one of the major factors hindering the growth of this market is Challenges in development of nanoparticles for therapeutics. Although nanoparticle-based therapeutics overcome biological barriers by effectively delivering hydrophobic drugs at preferentially target sites of disease, only a small number of nanoparticle-based medicines have been approved for clinical use.

Manufacturers of nanoparticles face numerous challenges and hurdles at different stages of product development. The complexity of nanoparticles requires careful design and engineering for their three-dimensional construction.

Their development requires detailed analysis of orthogonal methods, pharmacological profiles, and biological behaviors. Nanoparticles require detailed characterization and the successful manufacture of these complex constructs.

Access the Report @ marketreportscenter.com/request-discount/564967

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors."

News From

Market Reports Center - One Stop Shop for all market research needsMarket Reports Center
Category: Market Research Publishers and RetailersCompany about: Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable. Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals ...
This email address is being protected from spambots. You need JavaScript enabled to view it.